https://doi.org/10.55788/02614376
The phase 3 KEYNOTE-564 trial (NCT03142334) enrolled patients with intermediate-high- or high-risk RCC, a group in whom until recently no standard-of-care existed after surgery, explained Prof. Thomas Powles (Barts Cancer Institute, UK). Participants were randomised to adjuvant pembrolizumab (n=496) or placebo (n=498). The primary analysis, published in the New England Journal of Medicine, displayed a significant disease-free survival (DFS) benefit for patients who were treated with pembrolizumab over those who received placebo [2].
After 30.1 months of follow-up, the trial update indicated that DFS was still significantly higher in the pembrolizumab arm than in the placebo arm (HR 0.63; P<0.0001), with corresponding 24-month DFS rates of 78.3% and 67.3%. This result was consistent across subgroups, including disease risk category and PD-L1 status. Importantly, an exploratory analysis indicated that the rate of distant recurrences was higher in the placebo arm than in the pembrolizumab arm (HR 0.63), both in patients with M0-disease (n=936; 29.0% vs 20.8%) and in patients with M1-disease (n=58; 55.2% vs 20.7%). Prof. Powles added that the overall survival results were not yet mature, with 66 of the 200 needed events registered to date, but that a promising trend could be observed (HR 0.52; 95% CI 0.31–0.86).
The updated safety analysis did not reveal a substantial increase in adverse events (AEs). Fatigue (20.3%), pruritis (18.6%), hypothyroidism (17.4%), diarrhoea (15.8%), and rash (15.0%) were the most common any-grade AEs in the pembrolizumab arm.
- Powles T, et al. Pembrolizumab (pembro) as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Updated results from the 30-month follow-up of KEYNOTE-564. Game-changing session 2, EAU 2022, 01–04 July.
- Chouieri TK, et al. N Engl J Med 2021;385:683–694.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Fewer complications with robotic surgery in renal cancer Next Article
New prognostication in N3 penile cancer »
« Fewer complications with robotic surgery in renal cancer Next Article
New prognostication in N3 penile cancer »
Table of Contents: EAU 2022
Featured articles
Darolutamide performs well across subgroups in mHSPC
Genitourinary Cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Functional Urology
Novel therapeutic targets for benign prostatic hyperplasia
Mini-slings non-inferior to standard mid-urethral slings in SUI
Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs
Related Articles
August 24, 2020
HoLEP versus PVP in prospective randomised trial
March 4, 2022
Rezum therapy an option for benign prostatic hyperplasia
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy